Psychiatry · Disruptive Mood Dysregulation Disorder
This clinical trial addresses a critical gap in the treatment of Disruptive Mood Dysregulation Disorder (DMDD) in youth, which could lead to new therapeutic protocols. The outcomes may influence treatment guidelines and create opportunities for further research and funding in the mental health sector.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/1/2026, 12:33:06 PM
Assessment confidence: 58% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
This clinical trial addresses a critical gap in the treatment of Disruptive Mood Dysregulation Disorder (DMDD) in youth, which could lead to new therapeutic protocols. The outcomes may influence treatment guidelines and create opportunities for further research and funding in the mental health sector. Assessment grounded in 3 ranked evidence items (1 high-relevance).
Success in this trial could lead to the development of new therapeutic protocols, influencing treatment guidelines and creating opportunities for further research and funding. The strongest clinical anchor is Psychological Treatments for Youth With Severe Irritability. (ClinicalTrials.gov), sub-indication match (ild); entity match (disruptive mood dysregulation disorder).
The most relevant competitive pressure comes from Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders (Lilly) — sponsor/company relevance (lilly). This trial addresses a significant gap in psychological treatments for DMDD, potentially positioning the sponsoring institution as a leader in this niche area of mental health.
Regulatory risk is concentrated around If the trial demonstrates efficacy, it may prompt updates to treatment guidelines and influence regulatory approvals for new therapeutic approaches in managing DMDD..
No evidence in this category.
Psychological Treatments for Youth With Severe Irritability.
ClinicalTrials.govhigh relevance
Sub-indication match (ild); Entity match (disruptive mood dysregulation disorder)
FDA document
View sourceTrial of Management of Chronic Tinnitus by Sound Therapy and Cognitive Behavioral Therapy
ClinicalTrials.govmedium relevance
Entity match (cognitive behavioral therapy)
FDA document
View sourceCuidar-ME, Web-based Psychological Intervention for (Peri)Menopausal Women: A Pilot Randomized Controlled Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceBeeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceTirzepatide in the Treatment of Cannabis Use Disorder: A Proof-of-Concept Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceNarcolepsy Nightmare Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceNon-Inferiority Trial of TrIGR for PTSD
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceLilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lillymedium relevance
Sponsor/company relevance (Lilly)
FDA document
View sourcePhase 3 Trial of Navenibart for Hereditary Angioedema Initiated by Astria Therapeutics
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAmino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceElevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceGut Proteobacteria glycine metabolism regulates neuroplasticity, motivation, and reinstatement of cocaine self-administration in mice.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceRBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThis clinical trial addresses a critical gap in the treatment of Disruptive Mood Dysregulation Disorder (DMDD) in youth, which could lead to new therapeutic protocols. The outcomes may influence treatment guidelines and create opportunities for further research and funding in the mental health sector.
Successful outcomes could enhance market positioning for therapies targeting DMDD, potentially leading to increased revenue streams and market share for companies involved in mental health treatments.
If the trial demonstrates efficacy, it may prompt updates to treatment guidelines and influence regulatory approvals for new therapeutic approaches in managing DMDD.
Monitor trial outcomes, participant feedback, and any subsequent publications or treatment guidelines that emerge from this research.
Track for follow-up milestones; no immediate action required.